⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
businesswire.com
INCY
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
prnewswire.com
INCY
Resumen: Incyte anuncia la aprobación de la FDA para Jakafi XR™ (ruxolitinib) en comprimidos de liberación prolongada para tratar la mielofibrosis, la policitemia vera y la enfermedad de injerto contra huésped
businesswire.com
INCY
Incyte gibt die FDA-Zulassung von Jakafi XR™ (Ruxolitinib) Retardtabletten zur Behandlung von Myelofibrose, Polycythaemia vera und Graft-versus-Host-Erkrankung bekannt
businesswire.com
INCY
Riassunto: Incyte annuncia l'approvazione dell'FDA di Jakafi XR™ (ruxolitinib) compresse a rilascio prolungato per il trattamento della mielofibrosi, della policitemia vera e della malattia del trapianto contro l'ospite
businesswire.com
INCY
Incyte annonce l’autorisation par la FDA des comprimés à libération prolongée Jakafi XR™ (ruxolitinib) pour le traitement de la myélofibrose, de la polycythémie vraie et de la maladie du greffon contre l’hôte
businesswire.com
INCY
Samenvatting: Incyte maakt bekend dat de FDA goedkeuring heeft verleend voor Jakafi XR™ (ruxolitinib) tabletten met vertraagde afgifte voor de behandeling van myelofibrose, polycythemia vera en graft-versus-hostziekte
businesswire.com
INCY
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
businesswire.com
INCY
Form 8-K
sec.gov
VRTX
INCY